Učitavanje...

INNV-21. IN NEWLY-DIAGNOSED GLIOBLASTOMA, FRAILTY/SARCOPENIA PREDICTS 30D MORBIDITY & 30D, 90D, AND OVERALL MORTALITY AS ACCURATELY AS CURRENT STANDARDS

INTRODUCTION: Identification of novel prognostic biomarkers for glioblastoma (GBM) could stratify patients between aggressive or palliative treatments. Frailty, as measured by sarcopenia (lack of muscle mass), has been proven to predict survival in cancers. We evaluate whether the frailty/sarcopenia...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Zakaria, Hesham, Chandra, Ankush, Macki, Mohamed, Robin, Adam, Walbert, Tobias, Chang, Victor, Kalkanis, Steven, Lee, Ian
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847745/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.564
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!